NEW YORK (GenomeWeb News) – Nanogen today said it will market point-of-care tests for drugs of abuse made by American Bio Medica into the "hospital-related" setting.
Nanogen will re-brand the tests under its Tox STATus name and sell them using its existing sales force and distribution network. American Bio Medica will continue to sell the tests under their original brand to its core criminal justice and workplace markets, a spokesperson for the company said.
The tests, which are cleared by US and European regulators, can detect up to 15 commonly abused substances including cocaine, methamphetamine, and marijuana.
Nanogen said it expects to begin distributing the tests before the end of the year.
Financial terms of the deal were not disclosed.